Test Price
2,800 AED✅ Home Collection Available
COL4A2 Gene Porencephaly Type 2 Genetic Test in UAE – 2,800 AED
Executive Summary & Core Metrics
Advanced next-generation sequencing (NGS) genetic analysis targeting pathogenic variants in the COL4A2 gene associated with familial porencephaly type 2 and cerebrovascular malformations. Delivers definitive molecular diagnosis with 99.9% analytical sensitivity through an ISO 9001:2015 certified laboratory. Includes pre-test genetic counselling, VIP mobile phlebotomy home collection (8 AM – 11 PM), post-test telephonic clinical guidance, and direct insurance verification via WhatsApp +971 54 548 8731. Fully compliant with UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Price: 2,800 AED
Turnaround: 3-4 Weeks
Sample: Blood / Extracted DNA / FTA Card
Test Overview & Methodology
The COL4A2 NGS Test identifies pathogenic variants in the collagen type IV alpha 2 chain gene linked to familial porencephaly type 2 and cerebrovascular malformations. This high-resolution sequencing covers all exons and intron-exon boundaries with comprehensive copy number variant (CNV) detection, delivering definitive molecular diagnosis for affected individuals, at-risk relatives, and preconception counselling. Results enable tailored neurological surveillance, early intervention planning, and accurate recurrence risk assessment within the UAE healthcare ecosystem.
| Feature | DNA Labs UAE (DHA Licensed) | Standard Laboratory Alternative |
|---|---|---|
| Technology | Next-Generation Sequencing (NGS) with full bioinformatics pipeline | Limited gene panel or single-gene Sanger |
| Coverage | All exons + 20 bp flanking introns, CNV detection | Selected hotspot regions only |
| Turnaround | 3-4 weeks | 4-6 weeks |
| Pre-test Genetic Counselling | Included (pedigree charting, risk assessment) | Often not provided |
| Post-test Clinical Guidance | Telephonic call with Consultant Medical Geneticist | Written report only |
Physician Insight & Safety Protocols
“Understanding a child’s neurodevelopmental prognosis is one of the most challenging moments for any family. The COL4A2 genetic test provides a molecular anchor for accurate diagnosis and family counselling. However, I always emphasise that results must be correlated with neuroimaging and clinical phenotype — no single laboratory test replaces a comprehensive paediatric neurology evaluation. Continue all prescribed anti-epileptic or anti-coagulant medications unless your treating physician advises otherwise.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
Do not discontinue prescribed medication (e.g., anticonvulsants, antiplatelet agents, anticoagulants) without explicit approval from your managing physician. Abrupt cessation may increase the risk of breakthrough seizures or thromboembolic events.
Exclusion Criteria & Emergency Red Flags
- Acute neurological emergency: Sudden severe headache, seizure, loss of consciousness — seek emergency care via 998, do not pursue elective testing.
- Pending neuroimaging: If MRI/CT reveals acute intracranial hemorrhage or stroke, defer genetic testing until patient is clinically stable.
- Inability to provide consent: Minors require legal guardian consent compliant with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Unstable psychiatric condition: Should be addressed and stabilised prior to elective genetic counselling.
- Red Flag Symptoms (call 998 immediately): Acute hemiparesis, thunderclap headache, febrile seizure with altered consciousness, sudden vision loss.
All home collections are performed by DHA-licensed phlebotomists under strict infection-control protocols. If you experience any distress during sample collection, inform the staff immediately.
Patient FAQ & Clinical Guidance
1. What is the clinical utility of COL4A2 genetic testing for porencephaly type 2 in children?
Snapshot Answer: This test confirms a definitive molecular diagnosis of COL4A2-related porencephaly, guiding neurologists in predicting recurrence risk, planning surveillance for stroke-like events, and offering targeted genetic counselling to affected families. The result directly informs prognosis and management strategies.
2. How does home sample collection work for this test, and is it covered by insurance in UAE?
Snapshot Answer: A DHA-licensed phlebotomist arrives at your residence between 8 AM – 11 PM, collects a blood sample under strict temperature-controlled cold-chain protocols, and delivers it to our ISO-certified laboratory. We verify insurance coverage directly via WhatsApp at +971 54 548 8731 and facilitate direct billing where applicable.
3. What preparation is needed before providing a sample for the COL4A2 genetic test?
Snapshot Answer: No fasting is required. Please bring a complete list of all current medications and the completed clinical history form provided after booking. A pre-test genetic counselling session will document your family pedigree and risk factors prior to sample collection.
4. When will I receive my results and how are they delivered?
Snapshot Answer: Results are typically available within 3-4 weeks from sample receipt. You will receive a comprehensive molecular report via secure digital delivery, followed by a telephonic consultation with a Consultant Medical Geneticist to discuss implications and next steps.
UAE Regulatory & Data Privacy Adherence
Your data security and regulatory compliance are foundational at DNA Labs UAE. This COL4A2 genetic test is performed under the oversight of the Dubai Health Authority (DHA) and adheres strictly to:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) — governing the collection, processing, and storage of your genetic and health information.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields — ensuring secure digital transmission and confidentiality of electronic medical records.
- Federal Decree-Law No. 4 of 2016 on Medical Liability — safeguarding patient consent, clinical safety, and professional accountability throughout the testing pathway.
All genetic data is encrypted, access-controlled, and retained only for the duration necessary to fulfil clinical and legal obligations. No genetic information is shared with third parties without your explicit written consent.
Clinical & Logistical Metadata
| Test Name | COL4A2 Gene Porencephaly Type 2 Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3-4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood / Extracted DNA / FTA Card |
| Methodology Used | Next-Generation Sequencing (NGS) – Full Exonic Coverage + CNV Detection |
| ICD-10-CM Code | Q04.6 (Congenital porencephaly) |
| LOINC Code | 81247-9 (COL4A1/COL4A2 sequencing gene panel) |
| DHA Facility License & Address | License No. 1143 — Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians